Konrad Glund
Keine laufenden Positionen mehr
Karriereverlauf von Konrad Glund
Ehemalige bekannte Positionen von Konrad Glund
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Vorstandsvorsitzender | 01.01.2006 | 30.04.2018 |
| Gründer | 25.07.1997 | 30.04.2018 | |
Prosidion Ltd.
 Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Corporate Officer/Principal | 01.08.2004 | - |
| Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - | - |
| IFB Halle GmbH | Vorstandsvorsitzender | - | - |
| Gründer | - | - |
Ausbildung von Konrad Glund
| Martin-Luther-Universität Halle-Wittenberg | Doctorate Degree |
Statistik
International
| Deutschland | 4 |
| Vereinigtes Königreich | 2 |
Operativ
| Chief Executive Officer | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| IFB Halle GmbH | |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
- Börse
- Insiders
- Konrad Glund
- Erfahrung
